Two Sigma Investments LP Purchases 111,657 Shares of GeneDx Holdings Corp. (NASDAQ:WGS)

Two Sigma Investments LP raised its holdings in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 276.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 152,073 shares of the company's stock after purchasing an additional 111,657 shares during the quarter. Two Sigma Investments LP owned approximately 0.55% of GeneDx worth $11,688,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. raised its position in GeneDx by 18.5% in the 4th quarter. Vanguard Group Inc. now owns 1,006,210 shares of the company's stock valued at $77,337,000 after purchasing an additional 156,768 shares during the last quarter. Summit Partners Public Asset Management LLC increased its stake in shares of GeneDx by 336.9% in the 4th quarter. Summit Partners Public Asset Management LLC now owns 755,564 shares of the company's stock valued at $58,073,000 after buying an additional 582,619 shares during the period. William Blair Investment Management LLC acquired a new stake in shares of GeneDx in the 4th quarter valued at $51,496,000. Lord Abbett & CO. LLC acquired a new stake in shares of GeneDx in the 4th quarter valued at $48,458,000. Finally, Fred Alger Management LLC increased its stake in shares of GeneDx by 38.5% in the 4th quarter. Fred Alger Management LLC now owns 546,054 shares of the company's stock valued at $41,970,000 after buying an additional 151,824 shares during the period. Institutional investors own 61.72% of the company's stock.

GeneDx Trading Up 0.2%

Shares of GeneDx stock traded up $0.11 during trading on Thursday, reaching $70.13. 88,449 shares of the company were exchanged, compared to its average volume of 766,259. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a twelve month low of $19.54 and a twelve month high of $117.75. The business has a 50-day moving average price of $83.05 and a 200-day moving average price of $82.20. The firm has a market capitalization of $2.00 billion, a price-to-earnings ratio of -35.70 and a beta of 1.96.

GeneDx (NASDAQ:WGS - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The company reported $0.28 EPS for the quarter, topping analysts' consensus estimates of $0.11 by $0.17. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The business had revenue of $87.12 million during the quarter, compared to analysts' expectations of $79.90 million. Sell-side analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Wall Street Analyst Weigh In

WGS has been the subject of several research reports. TD Securities lowered their target price on GeneDx from $135.00 to $110.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Wells Fargo & Company lowered their target price on GeneDx from $105.00 to $78.00 and set an "equal weight" rating for the company in a research note on Thursday, May 1st. Jefferies Financial Group raised GeneDx from a "hold" rating to a "buy" rating and set a $80.00 target price for the company in a research note on Friday, May 9th. The Goldman Sachs Group lifted their target price on GeneDx from $70.00 to $80.00 and gave the company a "neutral" rating in a research note on Wednesday, February 19th. Finally, Guggenheim began coverage on GeneDx in a research note on Thursday, May 15th. They issued a "buy" rating and a $88.00 target price for the company. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $86.75.

Insiders Place Their Bets

In other GeneDx news, CFO Kevin Feeley sold 388 shares of GeneDx stock in a transaction dated Tuesday, April 29th. The stock was sold at an average price of $113.09, for a total transaction of $43,878.92. Following the transaction, the chief financial officer now directly owns 3,337 shares in the company, valued at approximately $377,381.33. The trade was a 10.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Katherine Stueland sold 10,559 shares of GeneDx stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $96.71, for a total value of $1,021,160.89. Following the transaction, the chief executive officer now owns 14,865 shares in the company, valued at approximately $1,437,594.15. This represents a 41.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 139,390 shares of company stock worth $13,043,288. Corporate insiders own 29.60% of the company's stock.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.